AnyGen
What should a biotech investor deck template include?
A biotech investor deck template should explain one investable chain: an unmet patient or scientific need, a differentiated intervention, evidence that supports the thesis, a development plan, and the capital required to reach the next value-inflection point. Unlike a general startup deck, it must make biological, clinical, regulatory, manufacturing, and financing risk legible.
Use 12 core slides for a first investor meeting: investment thesis, unmet need, product or platform, mechanism and differentiation, evidence, development pipeline, development and regulatory plan, market and value, intellectual property and CMC, team, financing ask and use of proceeds, and milestones. Keep detailed assay methods, protocol design, patent claims, and extended data in backup slides.
| Slide | Investor question | Minimum proof to show |
|---|---|---|
| Investment thesis | Why this company now? | Lead program, indication, stage, differentiator, and round objective |
| Unmet need | Who lacks an adequate option? | Patient population, current standard of care, and treatment gap |
| Product and evidence | Why should this work? | Target, modality, comparator, key data readout, and study conditions |
| Pipeline and plan | What is the next decisive event? | Program stage, next study, endpoint, timing, and dependency |
| Ask and milestones | What does this round buy? | Dollar ask, runway, spend categories, and milestone-linked outcomes |
What is the best slide order for a biotech pitch deck?
Lead with the investable thesis before technical detail. An investor should understand the patient, program, stage, catalyst, and financing ask within the opening two slides; the remaining slides should provide the proof needed to test that thesis.
- 1. Investment thesis: state the program, indication, stage, differentiator, and current round in one sentence.
- 2. Unmet need: name the patient population, treatment pathway, current limitation, and why the gap matters.
- 3. Product or platform: show the lead asset, modality, delivery route, target, and product scope.
- 4. Mechanism and differentiation: compare your approach with standard of care and the most relevant competing approach.
- 5. Evidence: present the most decision-relevant data first, with model, n, controls, endpoint, units, and limitations.
- 6. Pipeline: place each program on one stage axis from discovery through commercialization and distinguish the lead program from optionality.
- 7. Development and regulatory plan: list the next study, primary readout, regulatory interaction if applicable, timing, cost driver, and decision gate.
- 8. Market and value: define the initial patient or customer segment, treatment setting, adoption logic, and expansion rationale.
- 9. IP and CMC: state patent ownership or license status, filing status, and manufacturing path.
- 10. Team: match named leaders and advisors to the next 18 to 24 months of execution.
- 11. Financing ask and use of proceeds: state the round amount, expected runway, milestone allocation, and financing assumptions.
- 12. Milestones and close: turn the round into three to five dated proof points and restate the investment thesis.
A 12-slide core deck is a practical first-meeting structure, not a universal rule. A 2025 Presentile life sciences template presents 16 editable slides; add backup slides when the investor needs more detail on assay methods, clinical design, CMC, patent scope, or competitive landscape.
How do you show biotech data without overclaiming?
Show decision-grade evidence, not a collage of favorable charts. Every chart should identify the experimental system, sample size, comparator, endpoint, statistical method where relevant, and the limitation that remains before the next development decision.
| Evidence type | Put on the slide | Do not imply |
|---|---|---|
| In vitro | Cell type, assay, concentration range, n, control, endpoint, replicate definition | Clinical efficacy or human exposure |
| In vivo | Species, disease model, dose, route, n, comparator, endpoint, observation window | Translation without explaining model relevance |
| Biomarker | Assay, baseline, change, sampling time, analytical validation status | Clinical benefit unless established |
| Early clinical | Population, cohort, dose, safety cutoff, efficacy cutoff, response criteria, follow-up | Durability before adequate follow-up |
| Platform evidence | What repeated across programs, what changed, and the selection rule | That all pipeline programs are equally validated |
Use a one-line evidence caption under every figure. Example formatting: In a mouse xenograft experiment, 10 animals per arm received vehicle or candidate BX-101 at 10 mg/kg twice weekly for 21 days; tumor-volume change was the endpoint. BX-101 is a fictional formatting example and must be replaced with your documented study record.
How should a biotech investor deck show pipeline, milestones, and use of proceeds?
Make the round a milestone-financing plan. Silicon Valley Bank’s life science fundraising guidance says timelines should include preclinical and clinical development milestones and the costs to achieve them. Show one stage-gated pipeline slide and one financing slide rather than combining every program and expense in a single graphic.
Copyable worked example: a USD 15.0 million seed round
| Use of proceeds | USD millions | Milestone unlocked |
|---|---|---|
| IND-enabling pharmacology and toxicology | 5.0 | Candidate package ready for IND preparation |
| CMC process development and GMP material | 3.5 | Clinical-supply readiness |
| IND preparation, regulatory and clinical operations | 2.5 | IND submission and site activation plan |
| Discovery-platform expansion | 1.5 | Second-program selection data |
| Team, G&A and contingency | 2.5 | 24-month operating runway |
This USD 15.0 million allocation is an illustrative calculation, not a biotech sector benchmark. The categories sum to USD 15.0 million. Replace the amounts, runway, dates, hiring assumptions, and milestone costs with your company budget, vendor quotes, development plan, and cash-burn forecast before presenting.
How does a life science pitch deck template differ from a biotech investor deck template?
A life science pitch deck template uses the same investor logic but changes the proof package by business model. Therapeutics emphasize target, translational evidence, clinical path, CMC, and IP; diagnostics emphasize clinical utility, validation, reimbursement, regulatory route, and adoption; research tools emphasize workflow, technical performance, repeatable demand, and sales economics.
| Life science model | Primary investor proof | Milestone slide emphasis |
|---|---|---|
| Therapeutics | Mechanism, translational evidence, clinical-development path | IND, first patient dosed, safety or efficacy readout |
| Diagnostics | Analytical validity, clinical validity, clinical utility | Validation study, regulatory submission, reimbursement or launch evidence |
| Research tools | Performance versus incumbent workflow and repeatability | Product release, beta conversion, instrument or consumable adoption |
| Synthetic biology platform | Design-build-test learning loop and program conversion | Lead-program selection, partner data, manufacturing scale-up |
Keep the 12-slide shell, then replace the evidence and development slides with the right proof pathway. A diagnostic company should not borrow a therapeutics-style clinical pipeline graphic if its decisive event is a prospective validation study. A platform company should identify the first program or customer wedge rather than relying on a generic technology diagram.
How do you create a biotech investor deck template with AnyGen?
Use AnyGen to turn a verified biotech investor deck outline into a first editable deck, then review every scientific, clinical, commercial, and financial statement against source data before sending it to investors.
What should you check before sending a biotech investor deck?
Run a final factual and financing check. A biotech investor will test whether the scientific slide, pipeline stage, budget, and milestones describe the same program at the same date; inconsistency is more damaging than a concise deck.
- The opening thesis names one lead asset or program, indication, stage, differentiation, and financing objective.
- Every figure identifies model, n, comparator, dose or exposure where relevant, endpoint, units, and date or cutoff.
- The pipeline uses consistent stages across the deck: discovery, lead optimization, candidate selection, IND-enabling, IND cleared, Phase 1, Phase 2, Phase 3, or commercial.
- The competitive comparison uses an explicit basis: modality, target, stage, route, dosing, evidence type, or label status.
- The IP slide distinguishes owned patents, licensed rights, applications, and planned filings; it does not overstate freedom to operate.
- The use-of-proceeds total equals the round ask, and every major spend category maps to a milestone.
- Dates are presented as target dates or expected quarters unless the event is completed and documented.
- Forward-looking claims, data rights, and confidentiality language have been reviewed by appropriate company, legal, and scientific stakeholders.
Frequently asked questions
What slides should a biotech investor deck template have?
Use 12 core slides: investment thesis, unmet need, product or platform, mechanism and differentiation, evidence, pipeline, development and regulatory plan, market and value, IP and CMC, team, financing ask and use of proceeds, and milestones.
How many slides should a biotech pitch deck be?
Use about 12 core slides for a first meeting and keep detailed science, study design, patent analysis, and full data tables in backup slides. The right count is the shortest deck that lets an investor test the investment thesis and next milestone.
What makes a biotech investor deck different from a SaaS pitch deck?
A biotech deck must show biological rationale, evidence quality, development and regulatory path, intellectual-property position, manufacturing considerations, and a milestone-linked financing plan. Revenue traction alone is usually not the primary proof for a preclinical or clinical program.
How do I present preclinical data in a biotech investor deck?
For each figure, state the model, sample size, control, dose or exposure where relevant, endpoint, units, observation period, and limitation. Do not represent in vitro or animal findings as human efficacy.
What belongs on a biotech use of proceeds slide?
List the round amount, spend categories, dollar amount per category, expected runway, and the milestone each category unlocks. Check that the allocations add exactly to the stated financing ask.
What is a life science pitch deck template?
It is a wider investor-deck framework for therapeutics, diagnostics, research tools, and platforms. The structure is similar, but the central proof changes: therapeutics focus on clinical development, diagnostics on validation and adoption, and tools on workflow performance and repeatable demand.
Should a biotech deck include market size?
Yes, but connect market size to a defined first indication, patient segment or customer workflow, treatment setting, and adoption mechanism. Do not use a large global market number as a substitute for a credible initial market.
Can AnyGen create a biotech investor deck template?
AnyGen can generate an editable 12-slide starting structure from your verified inputs and organize pipeline, evidence, milestone, and use-of-proceeds material. You must validate every scientific, clinical, financial, regulatory, and IP statement before investor use.